Analysis

Opus Genetics, Inc. (IRD) Stock Analysis

Opus Genetics, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to IRD.

websiteIRD/analysis/IRD

Opus Genetics, Inc.

Opus Genetics, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to IRD.

Stock profile

Ticker

IRD

Asset type

Stock

Market cap

$336.0M

Sector

Health Technology

Industry

Pharmaceuticals: Major

Currency

USD

Ticker listings

Opus Genetics, Inc. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • IRD primary listing
  • R3X1
  • A2QG4Z

Latest Opus Genetics, Inc. news

Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts

RESEARCH TRIANGLE PARK, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company ...

Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., May 28, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies to restore...

Opus Genetics to Present at the 2026 Jefferies Global Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company d...

Opus Genetics to Present at the RBC Capital Markets 2026 Global Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company d...

Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update

Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate

Research sections

Valuation

Review valuation context for Opus Genetics, Inc..

Future growth

Review future growth context for Opus Genetics, Inc..

Past performance

Review past performance context for Opus Genetics, Inc..

Financial health

Review financial health context for Opus Genetics, Inc..

Dividend

Review dividend context for Opus Genetics, Inc..

Management

Review management context for Opus Genetics, Inc..

Ownership

Review ownership context for Opus Genetics, Inc..

Other information

Review other information context for Opus Genetics, Inc..

Community

Review community context for Opus Genetics, Inc..